TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9726393
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily for 6 weeks
Study: 9726393
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 3 weeks
Study: 9726393
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 6 weeks
Study: 26360825
Drug: HOT meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOT meal containing 5.82 mg total capsaicinoids
Study: 25751199
Drug: Single-size diaphragm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-size diaphragm with acid-buffering gel
Study: 23524437
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of melatonin (1% orabase cream formula) once daily for 20 days
Study: 23524437
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of melatonin
Study: 17182805
Drug: Moderate consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate consumption of olive oil (25 mL/d)
Study: 1583252
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 micrograms once daily
Study: 31076272
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and locally administered corticosteroids
Study: 31076272
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid spray and antihistamine drugs
Study: 24837690
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg once a day for up to 21 days
Study: 23009311
Drug: Glycerol-based emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol-based emollient cream (Dexeryl, Pierre Fabre)
Study: 18090458
Drug: Stalevo 50
Normalized name: Stalevo 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stalevo 50 (LCE50; 50/12.5/200 mg)
Study: 18090458
Drug: Stalevo 100
Normalized name: Stalevo 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stalevo 100 (LCE100; 100/25/200 mg)
Study: 18090458
Drug: Stalevo 150
Normalized name: Stalevo 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stalevo 150 (LCE150; 150/37.5/200 mg)
Study: 18090458
Drug: Sinemet 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet 100 (LC100; 100/25 mg)
Study: 18090458
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (LCE50, LCE100, LCE150, LC100)
Study: 15096909
Drug: Cyclazocine (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine (0.2, 0.4 and 0.8 mg)
Study: 15096909
Drug: Hydromorphone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (5 and 15 mg)
Study: 15096909
Drug: Cyclazocine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine (0 mg pretreatment)
Study: 15096909
Drug: Cocaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (100 mg intranasal)
Study: 6138082
Drug: Midazolam 10
Normalized name: midazolam 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 10 mg (oral)
Study: 6138082
Drug: Midazolam 20
Normalized name: midazolam 200 mg/200 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 20 mg (oral)
Study: 6138082
Drug: Midazolam 40
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 40 mg (oral)
Study: 6138082
Drug: Midazolam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.15 mg kg‐1 (intravenous)
Study: 31874050
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU vitamin D3 pearl once weekly for 12 weeks
Study: 27753609
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (arm C)
Study: 16093267
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (5 mg Androderm)
Study: 10953135
Drug: 1 implant
Normalized name: LEUPROLIDE ACETATE 72 MILLIGRAM In 1 IMPLANT SUBCUTANEOUS IMPLANT [Viadur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 implant
Study: 10953135
Drug: 2 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 implants
Study: 1616516
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 50 gm every hour for 8 hours (cumulative dose 150 gm)
Study: 1616516
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 25 gm every 2 hours for 8 hours (cumulative dose 150 gm)
Study: 1616516
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 12.5 gm every hour for 8 hours (cumulative dose 150 gm)
Study: 1616516
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase (no activated charcoal, only aminophylline 8 mg/kg)
Study: 6437264
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium cromoglycate (200-1600 mg/24 h)
Study: 30107641
Drug: Single-step nasal
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-step nasal spray (SP)
Study: 30107641
Drug: Intramuscular simulated
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular simulated naloxone (IM)
Study: 30107641
Drug: Multi-step atomized
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multi-step atomized nasal spray (AT)
Study: 24033356
Drug: Fasudil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (30 mg intravenous administration)
Study: 17663619
Drug: Daily weighing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily weighing
Study: 16105050
Drug: irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: irbesartan 300 mg once daily
Study: 16105050
Drug: irbesartan 600
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: irbesartan 600 mg once daily
Study: 16105050
Drug: irbesartan 900
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: irbesartan 900 mg once daily
Study: 10658441
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment protocol (STP) with PGE1 alpha-ciclodestrina: 2-hour infusions (20 micrograms in the morning, 40 micrograms in the afternoon on the first day; 60 micrograms b.i.d. on the second day) for 2 days, repeated at weeks 4, 8, 12.
Study: 10658441
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment protocol (LTP) with PGE1 alpha-ciclodestrina: 2-hour infusions (60 micrograms PGE1 alpha-ciclodestrina, 5 days each week for 4 weeks, then twice a week for 4 weeks).
Study: 331627
Drug: Amikacin sulfate
Normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin sulfate (15 mg./Kg.)
Study: 331627
Drug: Amikacin sulfate
Normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin sulfate (7.5 mg./Kg.)
Study: 27884722
Drug: Sequential anthracycline-taxane
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential anthracycline-taxane chemotherapy
Study: 27884722
Drug: Epirubicin/fluorouracil/cyclophosphamid chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin/fluorouracil/cyclophosphamid chemotherapy (FEC)
Study: 23063373
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, 8-day up-dosing schedule to 10,000 SQ-units (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-units at intervals of 2 and 4 weeks.
Study: 11522698
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin regimen
Study: 11522698
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin regimen
Study: 7944467
Drug: Intraarterial chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemotherapy with MTX, ADR, and CDDP
Study: 7944467
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of CDDP (more than 100 mg/m2)
Study: 7944467
Drug: Intraarterial chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemotherapy (general)
Study: 27655326
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied before plyometric exercise
Study: 27655326
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied after plyometric exercise
Study: 12081819
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g isolated soy protein (ISP)
Study: 12081819
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g isolated soy protein (ISP)
Study: 28864134
Drug: Left cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left cardiac sympathetic denervation (LCSD) as an adjunct to guideline recommended medical therapy
Study: 28864134
Drug: Guideline recommended
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline recommended medical therapy
Study: 23725997
Drug: Concurrent stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ)
Study: 21214392
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using a 50 mW 660 nm GaAlAs laser, irradiated at 1.75 W/cm² for 28 seconds per point, at three points around the cryosurgical site, immediately after treatment and at 48 and 72 hours post-treatment.
Study: 21214392
Drug: Cryosurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryosurgical treatment without LLLT (Non-LLLT group).
Study: 19447369
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using a bioadhesive patch loaded with 38 mg cm(‐2) aminolevulinic acid, administered in one or two cycles.
Study: 19447369
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using a bioadhesive patch loaded with 38 mg cm(‐2) aminolevulinic acid.
Study: 15717704
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg kg(‐1)
Study: 15717704
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg kg(‐1)
Study: 11258644
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1 g dose, 2 hours before exercise)
Study: 8026290
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (crossed over to polymeric dressing)
Study: 2531184
Drug: Cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5 mg daily)
Study: 3310586
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg daily)
Study: 4564559
Drug: ADV‐21 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV‐21 vaccine (10^6.4 TCID(50))
Study: 4564559
Drug: ADV‐21 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV‐21 vaccine (10^6.8 TCID(50))
Study: 4564559
Drug: ADV‐21 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV‐21 vaccine (10^4.6 TCID(50))
Study: 4564559
Drug: ADV‐21 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV‐21 vaccine (10^2.4 TCID(50))
Study: 24115184
Drug: Calcium 2000
Normalized name: calcium gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium 2000 mg/d
Study: 24115184
Drug: Calcium 2000
Normalized name: calcium gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium 2000 mg/d and Vitamin D3 800 IU/d
Study: 19537528
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (generic alternative)
Study: 19537528
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (standard preparation)
Study: 16740440
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation (DS) - 60 mg iron, 200 mcg folic acid, 1 mcg vitamin B12 daily
Study: 16740440
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation (WS) - two tablets once weekly
Study: 9547830
Drug: Other factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other factors (e.g., heredity, social class, maternal age, etc.)
Study: 29133549
Drug: RG7667 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7667 (10 mg/kg of each antibody, 4 doses at transplant, 1, 4, and 8 weeks)
Study: 22299818
Drug: Transcranial laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial laser therapy (TLT)
Study: 21367352
Drug: Eszopiclone 3
Normalized name: eszopiclone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 3 mg at bedtime
Study: 18714238
Drug: Serial Concurrent
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial Concurrent Exercise (CE)
Study: 18714238
Drug: Integrated Concurrent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Concurrent Exercise (CE)
Study: 12882067
Drug: Gastric insufflation
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric insufflation of 350 mL of air
Study: 10837440
Drug: Cefdinir 300
Normalized name: cefdinir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir 300 mg bd for 5 days
Study: 10837440
Drug: Cefprozil 500
Normalized name: cefprozil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil 500 mg bd for 10 days
Study: 10203402
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g MgSO4
Study: 3011885
Drug: ACTH 1‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 1‐17 (random infusion)
Study: 3011885
Drug: Saline (random
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (random infusion)
Study: 24507091
Drug: Rifampicin 300
Normalized name: Rifampicin 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 300 mg twice daily
Study: 24507091
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mg riboflavin capsules)
Study: 23648372
Drug: Cannabis (115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis (115 mg Δ9-THC, twice daily)
Study: 16610922
Drug: Oxycodone-acetaminophen
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone-acetaminophen
Study: 11712308
Drug: Amilorid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amilorid (10 mg)
Study: 11712308
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (500 mg)
Study: 7874096
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg three times daily
Study: 1451725
Drug: MK-571 (L-660,711)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (L-660,711) administered intravenously, single doses up to 1500 mg
Study: 1451725
Drug: MK-571 (L-660,711)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (L-660,711) administered orally, multiple doses of 100, 300, and 600 mg t.i.d. for 31 doses
Study: 6837255
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml mepivacaine with adrenaline
Study: 6837255
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml mepivacaine with adrenaline
Study: 6837255
Drug: 80 ml
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 ml mepivacaine with adrenaline
Study: 6837255
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (20 ml, 40 ml, 80 ml)
Study: 29451912
Drug: Adjuvant imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant imatinib treatment for one or three years
Study: 26994121
Drug: Thienopyridine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienopyridine plus aspirin (after 12 months)
Study: 10195381
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 500 mg twice daily
Study: 10195381
Drug: Dexfenfluramine (DEX)
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (DEX) 15 mg thrice daily
Study: 2317464
Drug: Intravenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phenytoin sodium
Study: 7364321
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (0.3 mg per kg)
Study: 7364321
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (0.3 mg per kg)
Study: 29558241
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation treatment for 10 days
Study: 31068272
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg with co-formulated emtricitabine 200 mg and tenofovir alafenamide 25 mg
Study: 21861419
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (0.5 microg x kg(‐1) x hr(‐1))
Study: 21861419
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (0.4‐0.7 microg x kg(‐1) x hr(‐1) decreased to 0.2‐0.7 microg x kg(‐1) x hr(‐1))
Study: 21861419
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no continuous intravenous analgesia)
Study: 19623196
Drug: Psyllium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium treatment for 2 months
Study: 319120
Drug: Nomifensin, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensin, 75 mg/day
Study: 319120
Drug: Viloxazine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine, 150 mg/day
Study: 31308269
Drug: Ridge augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridge augmentation using non‐resorbable ePTFE membrane only
Study: 31308269
Drug: Ridge augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridge augmentation using ePTFE and tenting screw with bone graft Bio‐Oss mixed with autogenous bone particles
Study: 31308269
Drug: Ridge augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridge augmentation with a bone block
Study: 28450193
Drug: Daily deflazacort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily deflazacort
Study: 24898537
Drug: Odanacatib 50mg
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 50mg weekly (ODN)
Study: 22036245
Drug: Glimepiride/metformin 1/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride/metformin 1/500 mg SR
Study: 22036245
Drug: Glimepiride/metformin 2/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride/metformin 2/500 mg SR
Study: 16425133
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of H. pylori infection plus iron supplementation for 6 weeks
Study: 12868803
Drug: Docetaxel (substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (substituted for fluorouracil in combination with doxorubicin and cyclophosphamide)
Study: 1471549
Drug: Non-effervescent Antabuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-effervescent Antabuse tablets (400 mg DSF after overnight fast)
Study: 1471549
Drug: Effervescent Antabuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent Antabuse tablets (800 mg DSF after a light standardized meal)
Study: 24205185
Drug: MVA.HIVA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA.HIVA vaccine
Study: 22300892
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous administration of 12 million units (MU) IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Study: 22300892
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous administration of 9 MU IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Study: 22300892
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous administration of 6 MU IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Study: 22300892
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous administration of IFN‐α2b with ribavirin